21 May 2013
Keywords: XOMA Corp, XmetA, Glycemic control
Article | 12 March 2012
US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) announced that results from a study of XMetA, the company's fully-human ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 March 2012
20 May 2013
© 2013 thepharmaletter.com